drugset

drugset / Trial / NCT00481325

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325 ↗

Phase 2/3 Completed 260 enrolled Bristol-Myers Squibb

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder

Timeline

Start: 2007-07
Primary completion: 2008-03
Completion: 2008-03

Publications

Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010 May;27(5):417-25. doi: 10.1002/da.20695.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Escitalopram	Small molecule	20 mg	Oral
Subject	Pexacerfont	Small molecule	100 mg	Oral

Indications